Procyanidin C2

CAS No. 37064-31-6

Procyanidin C2( ——— )

Catalog No. M38750 CAS No. 37064-31-6

Procyanidin C2 is a phenol glycoside derived from Fagopyrum dibotrys (D. Don) Hara.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Procyanidin C2
  • Note
    Research use only, not for human use.
  • Brief Description
    Procyanidin C2 is a phenol glycoside derived from Fagopyrum dibotrys (D. Don) Hara.
  • Description
    Procyanidin C2 is a phenol glycoside derived from Fagopyrum dibotrys (D. Don) Hara.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    37064-31-6
  • Formula Weight
    866.772
  • Molecular Formula
    C45H38O18
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zheng Zhong Bai; et al. A phenolic glycoside from Fagopyrum dibotrys (D. Don) Hara. 2007;18(9):1087–1088.
molnova catalog
related products
  • V2 receptor (V2R) a...

    c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively.

  • N-Acetyl-β-Asp-Glu

    Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid).

  • Glaucine

    Glaucine has antitussive antioxidative potential and antiviral activities it may be an anti-arthritic agent it can enhance LPS and zymosan-induced IL-10 production. Glaucine can inhibit the migration and invasion of human breast cancer cells by MMP-9 inhibitory activity attenuating IκBα and NF-κB activities.